887 related articles for article (PubMed ID: 11836309)
1. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
[TBL] [Abstract][Full Text] [Related]
2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
3. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
4. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
5. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.
European and Middle East Orgalutran Study Group
Hum Reprod; 2001 Apr; 16(4):644-51. PubMed ID: 11278211
[TBL] [Abstract][Full Text] [Related]
6. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
[TBL] [Abstract][Full Text] [Related]
7. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
8. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
9. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
10. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
Griesinger G; Diedrich K; Devroey P; Kolibianakis EM
Hum Reprod Update; 2006; 12(2):159-68. PubMed ID: 16254001
[TBL] [Abstract][Full Text] [Related]
11. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
[TBL] [Abstract][Full Text] [Related]
12. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Borm G; Mannaerts B
Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
[TBL] [Abstract][Full Text] [Related]
13. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
14. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
Escudero EL; Boerrigter PJ; Bennink HJ; Epifanio R; Horcajadas JA; Olivennes F; Pellicer A; Simón C
J Clin Endocrinol Metab; 2005 Apr; 90(4):2081-8. PubMed ID: 15483085
[TBL] [Abstract][Full Text] [Related]
15. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
[TBL] [Abstract][Full Text] [Related]
16. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
17. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
18. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
19. Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin.
Nevo O; Eldar-Geva T; Kol S; Itskovitz-Eldor J
Fertil Steril; 2003 May; 79(5):1123-8. PubMed ID: 12738506
[TBL] [Abstract][Full Text] [Related]
20. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
